Saturday 17 October 2026
Export HAE’s income statement to Excel — free account
Haemonetics Corporation
HAE Healthcare Medical Devices
Haemonetics Corporation’s revenue for fiscal 2026 (year ended March 2026) was $1.3 billion, down 1.97% from fiscal 2025. In the quarter to June 2026, revenue grew 5.60%, EPS grew 2.86%, free cash flow grew 220.4% and total debt rose 27.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
118.28
3.01
−2.48%
Follow HAE
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 11.20% | 12.03% | 19.30% | 19.47% |
+8 more TTM periods Free account |
|
Piotroski F-Score |
7 | 6 | 7 | 7 | |
| 3.99% | 4.02% | 6.99% | 6.77% | ||
ROIC |
5.62% | 5.53% | 10.69% | 10.30% | |
Return on Tangible Assets |
11.31% | 11.34% | 25.03% | 26.12% | |
Average Days of Receivables |
58.33 | 59.33 | 54.19 | 56.92 | |
Free Cash Flow per Share |
6.45 | 5.55 | 6.65 | 5.45 | |
Free Cash Flow |
292.53 | 261.82 | 311.38 | 259.20 | |
Capital Expenditures |
(35.62) | (31.40) | (27.46) | (29.84) | |
| Other line items | |||||
Cash ROIC |
13.12% | 11.58% | 14.19% | 12.55% | |
Accounts Receivable Turnover |
6.49 | 6.36 | 6.47 | 6.31 | |
Accounts Payable Turnover |
10.82 | 9.26 | 9.60 | 8.47 | |
Inventory Turnover |
1.66 | 1.63 | 1.57 | 1.54 | |
Average Days of Payables |
37.13 | 34.10 | 33.17 | 40.63 | |
Days of Inventory on Hand |
202.14 | 204.64 | 218.78 | 221.40 | |
Tax Rate |
(0.26) | (0.24) | (0.23) | (0.23) | |
Research and Development Expense of Revenue |
4.42% | 4.48% | 4.83% | 4.92% | |
Selling, General and Administrative Expense of Revenue |
33.33% | 33.16% | 33.12% | 32.68% | |
Share Based Compensation of Revenue |
2.50% | 2.54% | 2.40% | 2.41% | |
Interest Coverage |
5.36 | 5.46 | 10.49 | 9.47 | |
Operating CF/Net income |
3.41 | 3.01 | 1.93 | 1.72 | |
Depreciation/Fixed assets |
0.37 | 0.38 | 0.41 | 0.43 | |
Capex/Depreciation |
(0.31) | (0.27) | (0.23) | (0.24) | |
Revenue per Share |
29.81 | 28.28 | 28.17 | 27.90 | |
Operating CF per Share |
7.23 | 6.22 | 7.24 | 6.07 | |
Capex per Share |
(0.79) | (0.67) | (0.59) | (0.63) | |
Capex to Sales |
0.03 | 0.02 | 0.02 | 0.02 |
Columns are period end dates